Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Kenshi Suzuki

Tokyo, JP 
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Kenshi Suzuki practices in Tokyo, Japan. Suzuki is rated as an Advanced expert by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Their top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Agranulocytosis, Bone Marrow Transplant, and Tissue Biopsy.

Their clinical research consists of co-authoring 247 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Locations

Tokyo, Japan
Other Locations
Kawasaki, Japan
Nagoya, 4648602, Japan
Japan
Shibuya, 1508935, Japan
Chiba, Japan
Hamamatsu, 4328561, Japan
Okazaki, Japan
Shizuoka, Japan
Kashiwa, Japan
Toyoake, Japan
Tsukuba, 3058573, Japan
Naka, 3191195, Japan
Yokohama, 2408501, Japan
Shimotsuke, Japan
Wako, 3510198, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
View 1 Less Clinical Trial

247 Total Publications

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Suzuki's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile